Study guide
Section 9.4: Poison Prevention Packaging Act & Child-Resistant Containers
Texas MPJE Pharmacy Jurisprudence Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pharmacy Law Foundations & Regulators
Section 1.1: State and Federal Regulatory Bodies Section 1.2: Structure of Texas Pharmacy Law Section 1.3: TSBP Powers and Administrative Procedures Section 1.4: Inspections, Investigations, and Discipline
2 Chapter 2: Pharmacist Licensure & Continuing Education
Section 2.1: Initial Pharmacist Licensure & Reciprocity Section 2.2: License Renewal & Continuing Education Requirements Section 2.3: Inactive Status, Reinstatement, and Administrative Changes Section 2.4: Impaired Pharmacists & Peer Review Programs
3 Chapter 3: Pharmacy Personnel & Supervision Ratios
Section 3.1: Pharmacist-in-Charge (PIC) Responsibilities and Duties Section 3.2: Pharmacy Technicians and Technician Trainees Section 3.3: Pharmacist-to-Technician Supervision Ratios Section 3.4: Duties of Supportive Personnel
4 Chapter 4: Pharmacy Permits & Facility Classifications
Section 4.1: Texas Pharmacy Permit Classes Section 4.2: Class A (Community) Operations & Facilities Section 4.3: Class C (Institutional/Hospital) Operations & Facilities Section 4.4: Central Processing (Class G) and Non-Resident (Class E)
5 Chapter 5: Prescribers & Prescription Validity
Section 5.1: Texas Prescriptive Authority Section 5.2: General Prescription Requirements Section 5.3: Out-of-State and Canadian/Mexican Prescriptions Section 5.4: Self-Prescribing & Prescribing for Family Members
6 Chapter 6: Controlled Substances Schedules & Registration
Section 6.1: Federal vs. Texas Controlled Substances Schedules Section 6.2: DEA Registration & Texas Controlled Substances Act Section 6.3: Scheduled Listed Chemical Products Section 6.4: Controlled Substance Theft or Loss Reporting
7 Chapter 7: Controlled Substances Prescriptions & Dispensing
Section 7.1: CII Prescription Requirements and Validity Section 7.2: CII Refills, Partial Fills, and Emergency Oral Dispensing Section 7.3: CIII-CV Prescription Requirements, Validity, Refills, and Partial Fills Section 7.4: Opioid 10-day Initial Supply Limit & PMP Mandatory Queries
8 Chapter 8: Prescription Monitoring Program (PMP) & Drug Abuse
Section 8.1: Texas Prescription Monitoring Program Reporting & Database Section 8.2: Naloxone Access and Standing Orders in Texas Section 8.3: Corresponding Responsibility & Red Flags of Diversion Section 8.4: Treatment of Substance Use Disorders
9 Chapter 9: Dispensing Standards & Generic Substitution
Section 9.1: Texas Generic Substitution Law Section 9.2: Patient Counseling and Drug Utilization Review Requirements Section 9.3: Prescription Labeling Requirements in Texas Section 9.4: Poison Prevention Packaging Act & Child-Resistant Containers
10 Chapter 10: Prescription Refills, Transfers & Emergency Dispensing
Section 10.1: Prescription Refill Refusal & Professional Judgment Section 10.2: Prescription Transfer Rules Section 10.3: Emergency Refills (72-hour rule & 30-day natural disaster rule) Section 10.4: Return and Reuse of Prescription Medications
11 Chapter 11: Pharmacy Operations, Security & Recordkeeping
Section 11.1: Pharmacy Security, Alarms & Delivery of Drugs in Texas Section 11.2: General Recordkeeping & Document Retention Requirements Section 11.3: Controlled Substance Inventories Section 11.4: Disposal and Destruction of Controlled Substances
12 Chapter 12: Compounding Standards (Sterile & Non-Sterile)
Section 12.1: Non-Sterile Compounding Regulations Section 12.2: Sterile Compounding Regulations Section 12.3: Hazardous Drug Handling Section 12.4: Compounding Recordkeeping & Quality Control
13 Chapter 13: Specialized Pharmacy Practice & Public Safety
Section 13.1: Collaborative Practice Agreements & Drug Therapy Management Section 13.2: Pharmacist Immunization Authority & Protocol Requirements Section 13.3: Automated Dispensing Devices (Class A, C, and remote sites) Section 13.4: Public Health Laws (HIPAA, OBRA-90, DSCSA Drug Track and Trace)
Section 9.4: Poison Prevention Packaging Act & Child-Resistant Containers
Key Takeaways Explain This Topic AI
The Poison Prevention Packaging Act (PPPA) requires child-resistant (CR) packaging for most oral medications, defined by specific CPSC testing protocols.
Key exemptions include sublingual nitroglycerin, methylprednisolone dosepacks (max 84mg), and oral contraceptives in mnemonic dialpacks.
Patients can issue a written or verbal blanket request for all medications in non-CR containers; prescribers can only request it per individual prescription.
Plastic prescription vials and caps must never be reused for refills; glass containers can be reused but require a new plastic safety cap.
Medications dispensed to hospitalized inpatients are exempt from PPPA rules if administered by healthcare professionals.
Last updated: July 2026
Section 9.4: Poison Prevention Packaging Act & Child-Resistant Containers
The Poison Prevention Packaging Act of 1970 (PPPA) is a federal law aimed at protecting young children from accidental poisoning by household substances, including prescription and over-the-counter medications. Enforced by the Consumer Product Safety Commission (CPSC), the PPPA mandates the use of child-resistant (CR) packaging for most oral medications. Because the PPPA is a federal statute, compliance is enforced at both the federal level and by the Texas State Board of Pharmacy (TSBP) during routine pharmacy inspections.
Child-Resistant Packaging Standards and Testing
To be classified as "child-resistant," packaging must undergo rigorous testing using specific panels of children and adults. The standards are defined as follows:
Child Testing Panel: A panel of children aged 42 to 51 months is given 5 minutes to attempt to open the package. They are then given a visual demonstration of how to open it, and another 5 minutes. The packaging is considered child-resistant if at least 85% of the children cannot open it during the first 5 minutes, and at least 80% cannot open it after the demonstration.
Adult Testing Panel: A panel of adults aged 50 to 70 years is given 5 minutes to open and, if applicable, properly reclose the package. To ensure that child-resistant packaging does not prevent seniors from accessing their medications, at least 90% of the adult panel must be able to open and close the package successfully.
PPPA Drug Coverage and Exemptions
The PPPA applies to all oral prescription (legend) drugs and several categories of over-the-counter (OTC) medications. However, the law provides a comprehensive list of exemptions. These exemptions exist because certain medications are needed in acute emergencies where any delay in opening the container could result in severe harm or death, or because the drug has an extremely low toxicity profile.
Pharmacists must memorize the major exemptions for the MPJE:
Sublingual Nitroglycerin: All strengths of sublingual nitroglycerin tablets must be dispensed in non-child-resistant containers (typically the manufacturer's original glass bottle) because patients experiencing an acute angina attack must have immediate access to the drug.
Isosorbide Dinitrate: Sublingual and chewable forms of isosorbide dinitrate in strengths of 10 mg or less are exempt.
Methylprednisolone Tablets: Dosepacks containing not more than 84 mg of methylprednisolone (e.g., Medrol Dosepack) are exempt.
Oral Contraceptives: Estrogen-progestin oral contraceptives dispensed in manufacturer mnemonic (dialpack) dispenser packages are exempt.
Conjugated Estrogens: Tablets dispensed in mnemonic dispenser packages containing not more than 32 mg of conjugated estrogens are exempt.
Norethindrone Acetate: Tablets dispensed in mnemonic dispenser packages containing not more than 50 mg of norethindrone acetate are exempt.
Medroxyprogesterone Acetate: Medroxyprogesterone acetate tablets are exempt.
Potassium Supplements: Unit-dose forms (effervescent tablets, unit-dose liquids, and powders) containing not more than 50 mEq of potassium per unit dose are exempt.
Erythromycin Ethylsuccinate (EES):
Oral suspensions in packages containing not more than 8 grams of equivalent erythromycin are exempt.
Tablets in packages containing not more than 16 grams of equivalent erythromycin are exempt.
Anhydrous Cholestyramine: Powdered forms of anhydrous cholestyramine are exempt.
Colestipol: Powdered colestipol in packages containing not more than 5 grams of colestipol is exempt.
Sodium Fluoride: Liquid and tablet preparations containing not more than 264 mg of sodium fluoride per package are exempt.
Pancrelipase Preparations: All forms of pancrelipase (enzymes) are exempt.
Mebendazole: Tablets in packages containing not more than 600 mg of mebendazole are exempt.
Sacrosidase (Sucrase): Preparations in a solution of glycerol and water are exempt.
Hormone Replacement Therapy (HRT): Products that rely solely upon the activity of one or more progesterone or estrogen substances are exempt.
Note that non-oral dosage forms (e.g., topical ointments, creams, transdermal patches, eye drops, ear drops) are not covered by the PPPA's oral medication requirements, though they may be subject to other child-resistant regulations depending on their ingredients (e.g., iron-containing products).
Requests for Non-Child-Resistant Packaging
Under the PPPA, a pharmacy may dispense a covered oral medication in a non-child-resistant container under two specific circumstances:
1. Patient Requests
A patient or the patient's authorized representative can request that their medications be dispensed in non-child-resistant (easy-open) containers.
Individual vs. Blanket Request: A patient may request that a single prescription be dispensed in non-CR packaging, or they can issue a blanket request covering all current and future prescriptions filled at that pharmacy.
Documentation: A blanket request does not legally have to be in writing under federal law, but the TSBP and risk-management best practices strongly advise pharmacies to obtain a signed, written statement from the patient. The pharmacy must document the request on the patient's profile.
2. Practitioner Requests
A prescribing practitioner can request that a prescription be dispensed in non-child-resistant packaging.
Individual Request Only: A prescriber can only make a request for a single prescription and its refills . A practitioner cannot make a blanket request for all prescriptions written for a patient, nor can they make a blanket request for all patients in their practice.
Refills: The prescriber’s request is valid for the life of that specific prescription (including refills). Once the prescription expires and a new one is written, the prescriber must request non-CR packaging again if desired.
Reusing Prescription Containers
The PPPA establishes strict rules regarding the physical reuse of prescription vials and caps when refilling a prescription. The goal is to prevent wear and tear from compromising the child-resistant mechanism.
Plastic Vials and Caps: Must not be reused. Every time a prescription is filled or refilled, a brand new plastic vial and a brand new plastic cap must be used.
Glass Containers: May be reused, but the plastic safety cap must still be replaced with a new one.
Common Exam Traps and Legal Nuances
Institutional Exemptions: Medications dispensed to inpatients of hospitals or long-term care facilities are exempt from PPPA requirements, provided that the facility's personnel administer the medications directly to the patients. However, if a resident in a nursing home keeps their own medications at their bedside, those medications must be in child-resistant packaging.
OTC Products in Non-CR Packaging: The PPPA allows manufacturers of OTC products to package one size of an OTC product in non-child-resistant packaging, provided that the package bears the statement: "This package for households without young children" or "Package Not Child-Resistant" , and the manufacturer also offers the product in popular child-resistant sizes.
Nitroglycerin Forms: Only sublingual nitroglycerin tablets are exempt under the cardiac exception. Oral nitroglycerin sustained-release capsules or tablets are not exempt and must be dispensed in child-resistant packaging.
Civil Liability: Dispensing a medication in violation of the PPPA (e.g., failing to use a CR container without a request) is a federal violation and can lead to severe civil liability (malpractice) if a child is poisoned, in addition to TSBP disciplinary action.